• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Daxor Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    1/26/26 4:58:54 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care
    Get the next $DXR alert in real time by email
    false 0000027367 0000027367 2026-01-23 2026-01-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) January 23, 2026

     

    Daxor Corporation

     

    (Exact name of registrant as specified in its charter)

     

    New York   811-22684   13-2682108

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    107 Meco Lane, Oak Ridge, TN   37830
    (Address of principal executive offices)   (Zip Code)

     

    212-330-8500

     

    Registrant’s telephone number, including area code

     

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock $0.01 par value   DXR   Nasdaq

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     

     

     

     

     

    Item 1.01 – Entry Into a Definitive Material Agreement

     

    On January 23, 2026, Daxor Corporation (“we” or “us”) entered into a definitive securities purchase agreement with certain investors pursuant to which we issued and sold an aggregate of 765,958 registered shares of our common stock at $11.75 per share, through a registered direct offering, for net proceeds, after placement agent fees and expenses, of approximately $8,142,006. The closing took place on January 26, 2026. The shares of common stock offered by us in this transaction were registered under our shelf registration statement (File No. 333-281622) on Form N-2, which was declared effective by the Securities and Exchange Commission on January 20, 2026.

     

    Lake Street Capital Markets, LLC (“Lake Street”) acted as placement agent for the offering. On January 23, 2026, we executed a placement agency agreement with Lake Street.

     

    A copy of the form of securities purchase agreement and the placement agency agreement are filed herewith as Exhibits 10.1 and 10.2, respectively, and are incorporated herein by reference. The foregoing description of the offering by us, and the documents related thereto, is a summary and is qualified in its entirety by reference to such Exhibits.

     

    Item 8.01 – Other Events

     

    A copy of the opinion of Foley & Lardner LLP relating to the legality of the common stock is filed as Exhibit 5.1 to this report.

     

    Item 9.01 Exhibits

     

    (d) Exhibits. The following exhibit is filed with this Current Report on Form 8-K:

     

    No.   Description
         
    5.1   Opinion of Foley & Lardner LLP
    10.1   Form of Securities Purchase Agreement
    10.2   Placement Agency Agreement
    23.1   Consent of Foley & Lardner LLP (included in Exhibit 5.1)
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

      DAXOR CORPORATION
      (Registrant)
       
    Date: January 26, 2026 By: /s/ Robert J. Michel
      Name: Robert J. Michel
      Title: Chief Financial Officer

     

     

     

     

     

     

    Get the next $DXR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DXR
    SEC Filings

    View All

    SEC Form N-CSR filed by Daxor Corporation

    N-CSR - DAXOR CORP (0000027367) (Filer)

    3/2/26 4:37:20 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    SEC Form 40-8F-2 filed by Daxor Corporation

    40-8F-2 - DAXOR CORP (0000027367) (Filer)

    2/9/26 4:01:57 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - DAXOR CORP (0000027367) (Filer)

    1/26/26 4:58:54 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Michel Robert J bought 3,000 units of Daxor Common Stock, increasing direct ownership by 18% to 20,050 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    12/11/25 3:46:46 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Scientific Officer Feldschuh Jonathan Adam bought 18,000 units of Daxor Common Stock, increasing direct ownership by 50% to 53,908 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    12/11/25 3:41:44 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Jefferies John bought 2,344 units of Daxor Common Stock, increasing direct ownership by 15% to 17,616 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    11/14/25 5:22:37 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital initiated coverage on Daxor with a new price target

    Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00

    3/25/21 12:00:28 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $DXR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

    Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 2, 2026 from CEO & President, Michael Feldschuh. Dear Valued Shareholders, "To measure is to know. If you cannot measure it, you cannot improve it." — Lord Kelvin Lord Kelvin's timeless scientific principle perfectly encapsulates the mission of Daxor Corporation. In medicine, you cannot effectively treat what you cannot accurately measure. Looking back at the entirety of 2025, our commitment to replacing clinical guesswork with

    3/3/26 8:30:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share

    Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces financial and operating results for the fiscal year ended December 31, 2025. The company reported a transformative year characterized by significant growth in its operating division and a substantial increase in total net assets. FDA Milestone & Commercial Momentum The most significant corporate highlight of the year was the receipt of FDA 510(k) clearance in August 2025 for Daxor's next-generation rapid, compact, and

    3/3/26 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee

    Expansion Leverages Daxor's ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment  Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor's state-of-the-art testing to a high-volume preventative care setting, driving clinical excellence in chronic disease management. Utilizing Daxor's proprietary, Tennessee-based ezBVA Lab workflow, the facility will benefit from a 24-hour turnaround t

    2/24/26 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Michel Robert J bought 3,000 units of Daxor Common Stock, increasing direct ownership by 18% to 20,050 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    12/11/25 3:46:46 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Scientific Officer Feldschuh Jonathan Adam bought 18,000 units of Daxor Common Stock, increasing direct ownership by 50% to 53,908 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    12/11/25 3:41:44 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Jefferies John bought 2,344 units of Daxor Common Stock, increasing direct ownership by 15% to 17,616 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    11/14/25 5:22:37 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Financials

    Live finance-specific insights

    View All

    Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

    Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, "Patience, persistence and perspiration make an unbeatable combination for success." – Napoleon Hill. This timeless wisdom resonates deeply with the journey we've undertaken at Daxor Corporation, and it perfectly encapsulates the spirit behind our latest achievements. We are thrilled to share that this persistence has culminated in a truly transformative moment for our company, marking an important

    9/2/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

    Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023. The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. D

    3/4/25 4:55:00 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

    Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. After Management's presentation, there will be an opportunity for Q&A. Investors are encouraged to submit questions in advance via email to: [email protected]. To participate, register HERE. A webcast replay of the call will be available on the Company's website at Daxor.com. About Daxor Corporation Daxor Corporatio

    3/4/25 3:53:00 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Leadership Updates

    Live Leadership Updates

    View All

    Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer

    Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer. As part of his new responsibilities, Dr. Jefferies will leverage his extensive expertise to advise Daxor on strategic clinical and medical affairs matters and to facilitate the collaboration between the Company and healthcare professionals. He will be a key advisor, offering insights to inform corporate development strategies and advance the organization's growth objectives. Michael Fe

    6/5/24 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation Appoints Linda Cooper, Vice President Project Management

    Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. "Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda's proven track record makes her an excellent addition to the Daxor team to lead our development projects including our next generation systems, as well as overseeing our operations at our Oak Ridge facility," said Michael Feldschuh, CEO and President of Daxor Corporation. Before joining Daxor, Linda has held several senior leadersh

    2/17/23 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care